{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:08:30Z","timestamp":1793999310540,"version":"4.8.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2019,3,15]],"date-time":"2019-03-15T00:00:00Z","timestamp":1552608000000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"bioMeriuex, Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Staphylococcus aureus is among the most common human pathogens, with therapy complicated by the epidemic spread of methicillin-resistant Staphylococcus aureus (MRSA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The SENTRY Antimicrobial Surveillance Program evaluated the in vitro activity of &amp;gt;20 antimicrobials against 191 460 clinical S. aureus isolates collected from 427 centers in 45 countries from 1997 to 2016. Each center contributed isolates and clinical data for consecutive episodes of bacteremia, pneumonia in hospitalized patients, urinary tract infection, and skin and skin structure infection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 191 460 S. aureus isolates were collected, of which 77 146 (40.3%) were MRSA, varying geographically from 26.8% MRSA in Europe to 47.0% in North America. The highest percentage of MRSA was in nosocomial isolates from patients aged &amp;gt;80 years. Overall, MRSA occurrences increased from 33.1% in 1997\u20132000 to a high of 44.2% in 2005\u20132008, then declined to 42.3% and 39.0% in 2009\u20132012 and 2013\u20132016, respectively. S. aureus bacteremia had a similar trend, with nosocomial and community-onset MRSA rates peaking in 2005\u20132008 and then declining. Vancomycin activity against S. aureus remained stable (minimum inhibitory concentration [MIC]90 of 1 mg\/L and 100% susceptibility in 2016; no increase over time in isolates with a vancomycin MIC &amp;gt;1 mg\/L). Several agents introduced during the surveillance period exhibited in vitro potency against MRSA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In a large global surveillance program, the rise of MRSA as a proportion of all S. aureus peaked a decade ago and has declined since, consistent with some regional surveillance program reports. Vancomycin maintained high activity against S. aureus, and several newer agents exhibited excellent in vitro potencies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofy270","type":"journal-article","created":{"date-parts":[[2019,3,15]],"date-time":"2019-03-15T22:29:24Z","timestamp":1552688964000},"page":"S47-S53","source":"Crossref","is-referenced-by-count":204,"title":["Twenty-Year Trends in Antimicrobial Susceptibilities Among Staphylococcus aureus From the SENTRY Antimicrobial Surveillance Program"],"prefix":"10.1093","volume":"6","author":[{"given":"Daniel J","family":"Diekema","sequence":"first","affiliation":[{"name":"University of Iowa Carver College of Medicine, Iowa City, Iowa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A","family":"Pfaller","sequence":"additional","affiliation":[{"name":"University of Iowa Carver College of Medicine, Iowa City, Iowa"},{"name":"JMI Laboratories, North Liberty, Iowa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dee","family":"Shortridge","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Zervos","sequence":"additional","affiliation":[{"name":"Henry Ford Hospital, Detroit, Michigan"},{"name":"Wayne State University School of Medicine, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald N","family":"Jones","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,3,15]]},"reference":[{"key":"2020081004070240700_CIT0001","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/nrmicro2200","article-title":"Waves of resistance: Staphylococcus aureus in the antibiotic era","volume":"7","author":"Chambers","year":"2009","journal-title":"Nat Rev Microbiol"},{"key":"2020081004070240700_CIT0002","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1001\/jama.298.15.1763","article-title":"Invasive methicillin-resistant Staphylococcus aureus infections in the United States","volume":"298","author":"Klevens","year":"2007","journal-title":"JAMA"},{"key":"2020081004070240700_CIT0003","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3201\/eid0501.990102","article-title":"The economic impact of Staphylococcus aureus infection in New York City hospitals","volume":"5","author":"Rubin","year":"1999","journal-title":"Emerg Infect Dis"},{"key":"2020081004070240700_CIT0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/668770","article-title":"Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010","volume":"34","author":"Sievert","year":"2013","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2020081004070240700_CIT0005","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1017\/ice.2016.174","article-title":"Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014","volume":"37","author":"Weiner","year":"2016","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2020081004070240700_CIT0006","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1136\/jcp.14.4.385","article-title":"Methicillin-resistant staphylococci","volume":"14","author":"Barber","year":"1961","journal-title":"J Clin Pathol"},{"key":"2020081004070240700_CIT0007","first-page":"205","article-title":"Improved understanding of factors driving methicillin-resistant Staphylococcus aureus epidemic waves","volume":"5","author":"Chatterjee","year":"2013","journal-title":"Clin Epidemiol"},{"key":"2020081004070240700_CIT0008","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJM199808203390806","article-title":"Staphylococcus aureus infections","volume":"339","author":"Lowy","year":"1998","journal-title":"N Engl J Med"},{"key":"2020081004070240700_CIT0009","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1089\/mdr.2000.6.213","article-title":"Genetic relatedness of multidrug-resistant, methicillin (oxacillin)-resistant Staphylococcus aureus bloodstream isolates from SENTRY Antimicrobial Resistance Surveillance Centers worldwide, 1998","volume":"6","author":"Diekema","year":"2000","journal-title":"Microb Drug Resist"},{"key":"2020081004070240700_CIT0010","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.3201\/eid1510.080877","article-title":"Community-associated methicillin-resistant Staphylococcus aureus, Iowa, USA","volume":"15","author":"Van De Griend","year":"2009","journal-title":"Emerg Infect Dis"},{"key":"2020081004070240700_CIT0011","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1086\/675283","article-title":"Continued emergence of USA300 methicillin-resistant Staphylococcus aureus in the United States: results from a nationwide surveillance study","volume":"35","author":"Diekema","year":"2014","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2020081004070240700_CIT0012","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1128\/JCM.02187-13","article-title":"Report of the 13th vancomycin-resistant Staphylococcus aureus isolate from the United States","volume":"52","author":"Limbago","year":"2014","journal-title":"J Clin Microbiol"},{"key":"2020081004070240700_CIT0013","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1128\/AAC.00113-08","article-title":"Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin","volume":"52","author":"Lodise","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2020081004070240700_CIT0014","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.cmi.2017.06.017","article-title":"Evaluation of vancomycin MIC creep in methicillin-resistant Staphylococcus aureus infections-a systematic review and meta-analysis","volume":"24","author":"Diaz","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2020081004070240700_CIT0015","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.diagmicrobio.2018.01.029","article-title":"Oritavancin in vitro activity against gram-positive organisms from European and United States medical centers: results from the SENTRY Antimicrobial Surveillance Program for 2010-2014","volume":"91","author":"Pfaller","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2020081004070240700_CIT0016","doi-asserted-by":"crossref","first-page":"e01043","DOI":"10.1128\/AAC.01043-17","article-title":"Antimicrobial susceptibility trends among Staphylococcus aureus from U. S. hospitals: results from 7 years of the ceftaroline (AWARE) surveillance program (2010\u20132016)","volume":"61","author":"Sader","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020081004070240700_CIT0017","author":"US Census Bureau","year":"2015"},{"key":"2020081004070240700_CIT0018","volume-title":"Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard","author":"CLSI","year":"2018","edition":"11"},{"key":"2020081004070240700_CIT0019"},{"key":"2020081004070240700_CIT0020","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing: 28th Informational Supplement","author":"CLSI","year":"2018"},{"key":"2020081004070240700_CIT0021","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1001\/jama.2009.153","article-title":"Methicillin-resistant Staphylococcus aureus central line-associated bloodstream infections in US intensive care units, 1997-2007","volume":"301","author":"Burton","year":"2009","journal-title":"JAMA"},{"key":"2020081004070240700_CIT0022","doi-asserted-by":"crossref","first-page":"19819","DOI":"10.2807\/ese.16.11.19819-en","article-title":"Escherichia coli and Staphylococcus aureus: bad news and good news from the European Antimicrobial Resistance Surveillance Network (EARS-Net, formerly EARSS), 2002 to 2009","volume":"16","author":"Gagliotti","year":"2011","journal-title":"Euro Surveill"},{"key":"2020081004070240700_CIT0023","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1001\/jama.2010.1115","article-title":"Health care-associated invasive MRSA infections, 2005-2008","volume":"304","author":"Kallen","year":"2010","journal-title":"JAMA"},{"issue":"Suppl 2","key":"2020081004070240700_CIT0024","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.1086\/320184","article-title":"Survey of infections due to Staphyococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997\u20131999","volume":"32","author":"Diekema","year":"2001","journal-title":"Clin Infect Dis"},{"key":"2020081004070240700_CIT0025","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1093\/jac\/dkr561","article-title":"Mandatory surveillance of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in England: the first 10 years","volume":"67","author":"Johnson","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2020081004070240700_CIT0026","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa1007474","article-title":"Veterans Affairs initiative to prevent methicillin-resistant Staphylococcus aureus infections","volume":"364","author":"Jain","year":"2011","journal-title":"N Engl J Med"},{"key":"2020081004070240700_CIT0027","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ijantimicag.2018.04.003","article-title":"The impact of antibiotic prescription rates on the incidence of MRSA bloodstream infections: A county-level, US-wide analysis.","volume":"52","author":"Andreatos","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2020081004070240700_CIT0028","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2010.1125","article-title":"Decline in invasive MRSA infection: where to go from here?","volume":"304","author":"Perencevich","year":"2010","journal-title":"JAMA"},{"key":"2020081004070240700_CIT0029","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2020081004070240700_CIT0030","first-page":"3353","article-title":"Reappearance and treatment of penicillin-susceptible Staphylococcus aureus in a tertiary medical centre","volume":"70","author":"Chabot","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2020081004070240700_CIT0031","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.amjmed.2016.01.048","article-title":"Back to the future: penicillin-susceptible Staphylococcus aureus","volume":"129","author":"Cheng","year":"2016","journal-title":"Am J Med"},{"key":"2020081004070240700_CIT0032","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/jac\/dkt317","article-title":"Resurgence of penicillin-susceptible Staphylococcus aureus at a hospital in New York State, USA","volume":"69","author":"Crane","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2020081004070240700_CIT0033","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1080\/23744235.2017.1405276","article-title":"Trends in incidence and resistance patterns of Staphylococcus aureus bacteremia","volume":"50","author":"Jokinen","year":"2018","journal-title":"Infect Dis"},{"key":"2020081004070240700_CIT0034","doi-asserted-by":"crossref","first-page":"e01160","DOI":"10.1128\/JCM.01160-17","article-title":"Trends in antibiotic susceptibility in Staphylococcus aureus in Boston, Massachusetts, from 2000 to 2014","volume":"56","author":"Kanjilal","year":"2018","journal-title":"J Clin Microbiol"},{"key":"2020081004070240700_CIT0035","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1128\/JCM.03109-15","article-title":"Detection and prevalence of penicillin-susceptible Staphylococcus aureus in the United States in 2013","volume":"54","author":"Richter","year":"2016","journal-title":"J Clin Microbiol"},{"key":"2020081004070240700_CIT0036","article-title":"Clinical outcomes with penicillin versus alternative beta-lactams in the treatment of penicillin-susceptible Staphylococcus aureus bacteremia","author":"Shah","year":"","journal-title":"Pharmacotherapy"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/6\/Supplement_1\/S47\/33591028\/ofy270.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/6\/Supplement_1\/S47\/33591028\/ofy270.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T11:24:23Z","timestamp":1694690663000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/6\/Supplement_1\/S47\/5381623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":36,"journal-issue":{"issue":"Supplement_1","published-print":{"date-parts":[[2019,3,15]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofy270","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,3]]},"published":{"date-parts":[[2019,3]]}}}